MIRM Mirum Pharmaceuticals, Inc.
FY2025 10-K
Mirum Pharmaceuticals, Inc. (MIRM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core biopharma focused on rare diseases with three approved medicines: Livmarli, Cholbam, Ctexli
- • Acquired asset portfolios in 2023-2026: Travere’s bile acid medicines and Bluejay’s brelovitug for hepatitis D treatment
Risk Factors
- • Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law
- • Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals
Financial SummaryXBRL
Revenue
$521M
Net Income
-$23M
Operating Margin
-4.2%
Net Margin
-4.5%
ROE
-7.4%
Total Assets
$843M
EPS (Diluted)
$-0.47
Operating Cash Flow
$56M
Source: XBRL data from Mirum Pharmaceuticals, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Mirum Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.